MAM malfunction contributes to neuronal mortality and disease progression, whether through increased tethering (e.g., in AD), reduced connectivity (e.g., in PD and ALS), or structural interference by mutant proteins (e.g., in HD). This evidence concerns the gene SGCG and Huntington disease.